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Abstract
A novel bifunctional chelating agent bearing an aromatic ring has been synthesised and 
characterised. This ligand formed well-defined oxorhenium complexes. The analogous 99mTcO-
complex was obtained in an excellent yield with high radiochemical purity (>95%). The 
biodistribution of the 99mTc-complex after intravenous injection studied in normal rats showed 
that the activity was excreted mainly via renal-urinary pathway indicating its use for labelling 
peptides with 99mTc. 
Graphical abstract
In this paper, we report a convenient synthesis of a novel semi-rigid bifunctional chelating agent, 
their complexes with rhenium (V) and the in vivo behaviour in normal rats of the corresponding 
99mTcO-complex.
Keywords: Radiopharmaceuticals; Technetium-99m; Rhenium; Bifunctional chelating agent; 
Metallic complexes 
1. Introduction 
2. Results and discussion 
2.1. BFCA synthesis 
2.2. Rhenium chemistry 
2.3. 99mTc radiolabelling and biodistribution in rats
3. Conclusion 
4. Experimental 
4.1. Ethyl 4-hydroxy-3-nitrobenzoate 1 
4.2. Ethyl 3-amino-4-hydroxybenzoate 2 
4.3. Ethyl 3{2-[(triphenylmethylsulfanyl)methylcarbonylamino]ethanamido}-4-hydroxybenzoate 4 
4.4. 3-{2-[(triphenylmethylsulfanyl)methylcarbonylamino]ethanamido}-4-hydroxybenzoic acid 5 
4.5. [iPrNH2][ReO{(COOH)Ph-ON2S}] 6 
4.6. [PPh4][ReO{(COOH)Ph-ON2S}] 7 
4.7. 99mTc labelling 
4.8. Biodistribution in healthy rats
References
1. Introduction
There is a great current interest in the use of bifunctional chelating agents (BFCAs) in labelling of 
peptides and proteins with technetium-99m and rhenium-186/188 for the development of target-
specific radioimaging/radiotherapeutic agents, respectively.1 The technetium-99m is the most 
important radionuclide in diagnostic nuclear medicine due to its ideal nuclear properties 
(T1/2 = 6 h, 140 KeV γ emitter, convenient availability from a commercial generator), while 
rhenium-186 (T1/2 = 3.78 days, β
− (91%) and γ (9%) emitter) and rhenium-188 (T1/2 = 16.98 h, β
− 
(85%) and γ (15%) emitter) are two of the most promising radionuclides for radiotherapy.1 and 2 
Typically, BFCAs are chelating ligands comprising a donor atom set to strongly coordinate the 
metal radioisotope and a functional group for attachment to a bio-targeting vector. The ability of a 
BFCA to avoid in vivo transchelation or in vivo dissociation of the radionuclide is crucial. So, an 
ideal BFCA is one which is able to form a stable and inert complex in high yield, under mild 
conditions, without the formation of isomers. However, although several designs have been used 
in practice with success, BFCAs for technetium and rhenium that meet all these criteria do not 
exist yet. Consequently, it is of high priority to develop novel, high stability chelators for these 
two nuclides for subsequent use in diagnostic and therapy, respectively. 
It is well known that a semi-rigid structure provides a significant increase for the stability of their 
complexes.3 Most of the semi-rigid polydentate ligands are based on a cycloalkyl ring4 
(cyclohexane, cyclopentane…) instead of a benzene skeleton.5 To our knowledge, to include an 
aromatic cycle in the chelate ring compared to the cycloalkyl moiety presents two advantages: its 
ease of functionalisation, which is an essential feature for coupling the ligand to the target 
molecule, and the fact that this ligand system does not lead to the formation of syn/anti isomers. 
In connection with our interest in the preparation of new substitution-inert technetium and 
rhenium compounds, we have reported, in previous works,6 and 7 the synthesis of a new family of 
nonfunctionalised semi-rigid Ph-XN2S-type ligands (X = O, N or S) characterised by the presence 
of an aromatic cycle in the framework to favour and stabilise the chelate ring of the corresponding 
complexes by an entropic effect. The reactivity of these ligands with technetium-99m and the 
stability of the corresponding radiocomplexes were also investigated. These ligands produced 
unique and highly stable mono oxotechnetium complexes in the following order for the ortho 
substituent: OH > NH2 > Strt.
7 
In order to label biomolecules with technetium-99m or rhenium-186/188 via this kind of ligand, 
we decided to develop a novel BFCA derived from our best candidate Ph-ON2S. The 
functionalisation of multidentate ligands often needs time-consuming multistep syntheses. So, the 
aim of this work was to produce an easily synthesised BFCA derived from Ph-ON2S and to 
characterise its suitability to complex Tc and Re. In this paper, we report a simple and convenient 
route of such a ligand, their complexes with rhenium (V) and the in vivo behaviour in normal rats 
of the corresponding 99mTcO-complex. 
2. Results and discussion
2.1. BFCA synthesis
To link to the target molecule, we selected the carbonyl group since many biomolecules contain 
amino groups available for amide bond formation. The synthesis of compound 5 was performed 
in seven steps as outlined in Scheme 1. 
Scheme 1. Synthetic route of ligand 5. Reagents and conditions: (i) HClg, EtOH, 40%; 
(ii) HClg, EtOH, 95%; (iii) H2, Pd/C, MeOH, 92%; (iv) Et3N, THF/DMF, rt, 98%; (v) 
NaOH 1 M, MeOH, 50 °C then HCl 6 M, 99%; (vi) NHS/DCC, THF, rt, 85%; (vii) 3, 
DMAP, 60°, CH3CN, 92%; (viii) NaOH 1 M, MeOH, 75° then HCl 3 M, 63%. 
The first key step was the preparation of ethyl 3-amino-4-hydroxybenzoate 2. Papachristou and 
coll.8 proposed a one-step synthesis for the structural isomer ethyl 4-amino-3-hydroxybenzoate by 
refluxing 4-amino-3-hydroxybenzoic acid in ethanol in the presence of HCl. Anyway, neither 
yield nor experimental or spectroscopic details were given. Despite the apparent simplicity of this 
method, compound 2 has never been obtained from commercially available 3-amino-4-
hydroxybenzoic acid, in this way, with satisfactory yields (40% maximum). So, an alternative 
pathway was investigated to prepare this compound in excellent yield. The synthesis of 2 
involved a two-step reaction procedure. The first step consisted in protection of the carboxylic 
acid function of 4-hydroxy-3-nitrobenzoic acid by a classical acid esterification reaction in 
ethanol, giving 1. The second step consisted in reduction of the nitro function of 1 by a palladium 
on charcoal-promoted hydrogenation reaction in MeOH. The synthesis of precursor 2 was 
achieved with a global yield of 87%. 
Precursor 3 was prepared in three steps from a previously described protocol.7 After an amide 
coupling reaction between ethyl glycinate and N-hydroxysuccinimidyl-2-
(triphenylmethylthio)ethanoate9 in the presence of Et3N in a THF/DMF mixture, basic hydrolysis 
of the ethyl ester function followed by the activation of the acid function with NHS-DCC 
afforded the precursor 3 in 82% overall yield. The aromatic core 2 reacted with intermediate 3 in 
the presence of DMAP in acetonitrile to give 4 in 92% yield. 
The final step consisted in a basic hydrolysis reaction. Several classical saponification 
conditions10 (KOH or NaOH in alcohol at rt) were attempted to obtain the carboxylic acid 5, but 
without success. Recently, Ziessel reported an alternative method to hydrolyse similar ethyl esters 
(ethyl aryl esters bearing amide functions on the aromatic core) using a large excess of NaOH 
(50 equiv) in a mixture of water and THF at reflux.11 According to this methodology, we have 
performed the saponification by heating compound 4 in the presence of an excess of NaOH using 
methanol or THF/MeOH mixture as a solvent. The progress of the reaction, followed by TLC, 
showed that a temperature 75 °C is required. Under this temperature, the saponification only 
occurred partially. After 4 h at 75 °C in methanol, all the starting material 4 was consumed. 
Controlled acidification then provided the expected acid 5, which was isolated pure by column 
chromatography with an acceptable yield (63%). Analytical studies indicate, without ambiguity, 
formation of the expected carboxylic acid 5. However, we have noticed the formation of by-
products as responsible for the significant decrease of the isolated yield. 2-
(Triphenylmethylthio)ethanoic acid, resulting in the break of the non-aromatic amide bond of 
compound 4 during saponification step, was isolated in 10% yield and clearly identified by proton 
NMR. 
The BFCA 5 was performed in seven steps with an overall yield of 42%, is stable at room 
temperature and does not require any particular condition for long-term storage. 
2.2. Rhenium chemistry
The oxorhenium complex 6 was synthesised in good yield using a ligand exchange reaction with 
our ligand 5 and a slight excess of labile ReO(PPh3)2Cl3 
12 in the presence of diisopropylamine as 
deprotonating agent (Scheme 2). In these conditions, the cleavage of trityl group was 
accomplished during the coordination of the ligand to the ReO3+ core and this is in agreement 
with the acidic contribution of the metal in the mechanism of sulfur detritylation.13 The presence 
of diisopropylammonium chloride as a persistent contaminant, even after column chromatography 
purification, suggested the replacement of the countercation with larger PPh4
+. The exchange 
reactions were performed in dichloromethane/methanol solutions at room temperature. Under 
these conditions, analytically pure complex 7 was obtained in 69% yield (Scheme 2). 
Scheme 2. Preparation of the oxorhenium and oxotechnetium complexes. 
These two oxorhenium complexes were unambiguously identified by conventional analytical 
techniques and their spectroscopic characteristics were similar to those obtained for 
nonfunctionalised complexes,7 that is, the complexes exhibit a distorted square pyramidal 
geometry with yl-oxygen in the apical position. Briefly, IR spectra showed an intense band 
attributable to the Re O stretching vibration14 at 957 and 960 cm−1 for complexes 6 and 7, 
respectively. Methylene protons of the tetradentate ligand framework were found to be 
diastereotopic (AB pattern) with coupling constants in the range of 17–18.5 Hz. According to the 
literature,13 we assigned the downfield signal of both AB patterns to the endo protons (syn to the 
Re O group) and the upfield signals to the exo ones (anti to the Re O group). Finally, 
negative-ion electrospray of each complex presents two prominent ion peaks with an isotope 
distribution pattern consistent with the monomeric anion. 
As expected, this structural study confirmed the presence of a unique isomer with respect to the 
carbonyl function. Moreover, the carboxyl group does not coordinate to the rhenium core and thus 
it could be used for the coupling to a biomolecule. 
2.3. 99mTc radiolabelling and biodistribution in rats
Trityl deprotection and 99mTc-labelling of the ligand 5 were performed in situ in a 
methanol/buffer solution, pH 8.6 (1/4: v/v), by direct reduction of sodium pertechnetate in the 
presence of an excess of tin chloride at 40 °C during 30 min (Scheme 2). Under these mild 
conditions, the labelling reaction was quantitative and only one negatively charged 99mTcO-
product was observed. Purification of 99mTcO-complex 8 was accomplished by C-18 reverse-
phase HPLC and resulted in only one component with an excellent radiochemical purity (>95%). 
Preliminary biological evaluation of HPLC-isolated complex 8 was performed in healthy rats at 5 
and 30 min pi. Complex 8 showed a reasonably high liver uptake (14% ID at 5 min post-
injection), but was preferentially eliminated via the renal-urinary excretion route, as revealed by 
the 37% ID in urine at 30 min post-injection (Table 1), indicating the hydrophilic character of the 
radiocomplex. The higher concentration of radioactivity was measured in kidneys at all times 
studied (9.74, 2.89% ID/g). 
Table 1. 
Biodistribution data (% of ID/organ)a of the 99mTcO-complex 8 in normal rats at 
different time points (pi) 
5 min 30 min
Blood 29.54 ± 0.09 6.55 ± 0.45
Brain 0.06 ± 0.01 0.02 ± 0.01
Heart 0.41 ± 0.03 0.13 ± 0.01
Intestine 4.53 ± 0.17 15.74 ± 2.12
Kidneys 25.29 ± 2.48 7.26 ± 2.34
Liver 13.91 ± 1.37 4.7 ± 0.83
Lung 0.79 ± 0.12 0.37 ± 0.04
Pancreas 1.17 ± 0.17 0.57 ± 0.08
Spleen 0.20 ± 0.05 0.05 ± 0.01
Stomach 0.58 ± 0.20 0.51 ± 0.28
Urine 3.07 ± 1.18 37.15 ± 10.42
a Values represent means ± SD (n = 3). 
The rapid clearance of this compound from the bloodstream, reflected in the low blood activity, 
indicated its high stability against exchange reactions with blood proteins and no specific uptake 
or long-term retention in organs or tissues. The biodistribution studies also indicated that little, if 
any, in vivo decomposition of complex 8 occurred. The minimal activity accumulation in the 
stomach (0.51 ± 0.28% ID/organ at 30 min) and in spleen (0.05 ± 0.01% ID/organ at 30 min) 
indicated that 99mTcO4
− was not produced in relevant amount during biodistribution.15 The 
observed stability provides important evidence that this ligand system is capable of stabilising 
99mTc even under in vivo conditions. 
3. Conclusion
In short, the synthetic protocol described herein provides an easy access to an original BFCA 
including an aromatic cycle in the chelate ring, in seven steps with an overall yield of 42%, the 
rate-limiting step being the final hydrolysis step. This compound produced well-defined ReO 
complexes. Moreover, this BFCA formed a stable and inert 99mTcO-complex in high yield, under 
mild conditions, without the formation of isomers. In vivo study demonstrates the high stability of 
the radiocomplex and shows that this chelate is efficiently cleared to a great extent from the 
bloodstream via the renal-urinary excretion route and to a less extent via the hepatobiliary 
pathway. No specific uptake or retention in the kidneys or other organs was observed. All these 
significant results justify its use for labelling peptides with 99mTc. Development of new target-
specific radioimaging agents with this new kind of semi-rigid BCFA is currently underway and 
the results will be disclosed in the near future. 
4. Experimental
All chemicals were of the highest purity commercially available and all solvents were freshly 
distilled by standard methods before use. Column chromatography was carried out using ‘gravity’ 
silica (Merck). Rhenium(VII) oxide, purchased from Aldrich Chem. Co, was converted to 
ReOCl3(PPh3)2 according to published protocols.
12 The intermediate 3 has been prepared as 
described previously.7 NMR spectra were recorded on a Bruker AC 250 (62.896 MHz for 13C and 
250.133 MHz for 1H) or 400 (100.63 MHz for 13C and 400.133 MHz for 1H). Chemical shifts are 
indicated in δ values (ppm) downfield from internal TMS, and coupling constants (J) are given in 
Hertz (Hz). Infrared spectra were recorded as KBr pellets on a Bruker Vector 22 
spectrophotometer in the range 4000–400 cm−1. Negative electrospray or DCI-Mass spectra were 
obtained on a NERMAG R 10-10 mass spectrometer. Microanalysis was performed by the 
microanalytical department of the Ecole Nationale Supérieure de Chimie de Toulouse. HPLC 
analysis and purification were achieved on a Waters 600E gradient chromatography with a 
Waters Lambda Max UV detector, a SAIP radioactivity detector and an ICS dual integrator for 
effluent monitoring and a Satisfaction RP18AB column (5 μm, 125 × 4.6 mm) using MeOH–
H2O–TFA: 55/45/0.1 as eluent (flow rate of 1 mL/min). 
4.1. Ethyl 4-hydroxy-3-nitrobenzoate 1
A solution of 4-hydroxy-3-nitrobenzoic acid (5.00 g, 27.3 mmol) in freshly distilled ethanol 
(150 mL) was saturated in HClg. The mixture was stirred at room temperature overnight and then 
the solvent was removed under reduced pressure to give 1 as a yellow powder (5.48 g, 95%). 
1H NMR (250 MHz, CDCl3) δH (ppm): 1.40 (t, 3H, J = 7.1 Hz, CH3), 4.38 (q, 2H, J = 7.1 Hz, 
OCH2), 7.20 (d, 1H, J = 8.8 Hz, HAr), 8.22 (dd, 1H, J = 2.1 and 8.8 Hz, HAr), 8.80 (d, 1H, 
J = 2.1 Hz, HAr), 10.88 (s, 1H, OH); 
13C {1H} NMR (62.9 MHz, CDCl3) δC (ppm): 14.3 (CH3), 
61.7 (OCH2), 120.3, 127.3, 137.8 (3CHAr), 123.2, 133.2, 158.1 (3CAr), 164.4 (CO); MS 
(DCI/NH3): 229 [M+NH4
+]. 
4.2. Ethyl 3-amino-4-hydroxybenzoate 2
Catalytic hydrogenation of 1 (5.00 g, 23.7 mmol) in methanol (250 mL) over 10% Pd/C (20% 
w/w, 1.25 g) was carried out at atmospheric pressure. The mixture was stirred for 2 h, then the 
catalyst was filtered off through Celite and the solvent was removed under reduced pressure to 
give 2 as a grey solid (3.92 g, 92%). 
1H NMR (250 MHz, MeOD) δH (ppm): 1.33 (t, 3H, J = 7.1 Hz, CH3), 4.27 (q, 2H, J = 7.1 Hz, 
OCH2), 6.72 (d, 1H, J = 8.3 Hz, HAr), 7.30 (dd, 1H, J = 2.1 and 8.3 Hz, HAr), 7.40 (d, J = 2.1 Hz, 
HAr); 
13C {1H} NMR (62.9 MHz, MeOD) δC (ppm): 14.9 (CH3), 61.6 (OCH2), 114.7, 118.0, 
122.5 (3CHAr), 122.9, 136.4, 151.3 (3CAr), 168.8 (CO); MS (DCI/NH3): 182 [M+H
+], 199 
[M+NH4
+]. 
4.3. Ethyl 3{2-[(triphenylmethylsulfanyl)methylcarbonylamino]ethanamido}-4-
hydroxybenzoate 4
To a solution of 2 (0.50 g, 2.76 mmol) and 3 (1.35 g, 2.76 mmol) in acetonitrile (40 mL) was 
added DMAP (0.34 g, 2.76 mmol). The solution was heated at 60 °C, under nitrogen, for 3 h. 
After cooling, the product was left to precipitate overnight at −18 °C. After filtration, the 
precipitate was washed with cold acetonitrile and then purified by column chromatography on 
silica gel (CHCl3 then CHCl3–MeOH 95/5) to afford 4 as a white powder (1.41 g, 92%). 
1H NMR (250 MHz, DMSO-d6) δH (ppm): 1.28 (t, 3H, J = 7.1 Hz, CH3), 2.87 (s, 2H, CH2S), 
3.86 (d, 2H, J = 5.6 Hz, CH2N), 4.25 (q, 2H, J = 7.1 Hz, OCH2), 6.94 (d, 1H, J = 8.3 Hz, HAr), 
7.30 (m, 15H, HAr Trt), 7.58 (dd, 1H, J = 1.8 and 8.3 Hz, HAr), 8.35 (s, 1H, NH), 8.53 (d, 1H, 
J = 1.8 Hz, HAr), 9.25 (s, 1H, NH), 10.87 (s, 1H, OH); 
13C {1H} NMR (100.6 MHz, CDCl3) δC 
(ppm): 14.6 (CH3), 35.7 (CH2S), 44.6 (CH2N), 61.2 (OCH2), 68.3 (CTrt), 118.6 (CHAr), 122.6 
(CAr), 124.1 (CHAr), 125.5 (CAr), 128.6 (CHAr), 127.4, 128.5, 129.6 (15CHAr Trt), 143.9 (3CAr 
Trt), 152.6 (CAr), 166.5, 168.3, 170.3 (3CO); MS (DCI/NH3): 555 [M+H
+], 572 [M+NH4
+]. 
4.4. 3-{2-[(triphenylmethylsulfanyl)methylcarbonylamino]ethanamido}-4-hydroxybenzoic 
acid 5
To a solution of 4 (2.00 g, 3.61 mmol) in MeOH (180 mL) was added a solution of 1 N NaOH 
(140 mL). After 4 h at 75 °C, the mixture was cooled and 3 N HCl was added until the solution 
became acidic. The solution was concentrated (to eliminate the MeOH) and then extracted with 
AcOEt (4 × 60 mL). The organic layer was separated, dried over sodium sulfate, filtered off and 
concentrated to dryness under reduce pressure. The residue was purified by column 
chromatography on silica gel (CH2Cl2–AcOEt 6/4 then CH2Cl2–MeOH 95/5) to give 5 as a white 
powder (1.20 g, 63%). 
1H NMR (400 MHz, DMSO-d6) δH (ppm): 2.89 (s, 2H, CH2S), 3.85 (d, 2H, J = 5.4 Hz, CH2N), 
6.92 (d, 1H, J = 8.4 Hz, HAr), 7.33 (m, 16H, HAr + 15HAr Trt), 7.55 (d, 1H, J = 8.4 Hz, HAr), 8.35 
(s, 1H, NH), 8.49 (s, 1H, NH), 9.23 (s, 1H, OH); 13C {1H} NMR (100.6 MHz, DMSO-d6) δC 
(ppm): 36.5 (CH2S), 43.9 (CH2N), 66.7 (CTrt), 115.4 (CHAr), 121.9 (CAr), 123.5 (CHAr), 126.4 
(CAr), 127.1 (CHAr), 127.5, 128.8, 129.8 (15CHAr Trt), 144.7 (3CAr Trt), 151.1 (CAr), 168.2, 168.6 
(3CO); MS (DCI/NH3): 527 [M+H
+], 544 [M+NH4
+]; IR (KBr): νC O = 1683, 1652, 
1602 cm−1; elemental analysis found C, 68.37; H, 5.05; N, 4.96% C30H26N2O5S requires C, 
68.42; H, 4.98; N, 5.32%. 
4.5. [iPrNH2][ReO{(COOH)Ph-ON2S}] 6
To 5 (157.8 mg, 0.3 mmol) and diisopropylamine (1.68 mL, 0.12 mmol) dissolved in dry 
methanol (40 mL) was added ReOCl3(PPh3)2 (324.5 mg, 0.39 mmol). After refluxing for 4 h, the 
solution was cooled, filtered and then evaporated to dryness. The residue was purified by column 
chromatography on silica gel (eluent: CHCl3–MeOH: 95/15 then 90/10) to yield the complex 6 as 
a dark red powder (155 mg, 88%). 
1H RMN (400 MHz, MeOD): δH = 1.29 (m, 12H, CH3), 3.45 (m, 2H, CHN), 3.75 (d, 1H, 
J = 17.2 Hz, CH2S), 4.08 (d, 1H, J = 17.2 Hz, CH2S), 4.49 (d, 1H, J = 18.4 Hz, CH2N), 5.44 (d, 
1H, J = 18.4 Hz, CH2N), 7.04 (d, 1H, J = 8.2 Hz, HAr), 6.66 (dd, 1H, J = 8.2  and 1.8 Hz, HAr), 
8.90 (m, 1H, HAr); 
13C{1H} NMR (100.6 MHz, MeOD): δC = 8.0 (6CH3), 39.9 (CH2S), 46.8 
(2CHN), 60.6 (CH2N), 114.5, 119.5 (2CHAr), 121.4 (CAr), 126.1 (CHAr), 140.2, 169.4 (2 CAr), 
174.1, 187.2, 194.2 (3CO); MS (ES−), m/z (%): 481 (60), 483 (100) [M−]; IR (KBr): νRe
O = 960 cm
−1. 
4.6. [PPh4][ReO{(COOH)Ph-ON2S}] 7
Compound 6 (128.5 mg, 0.22 mmol) and tetraphenylphosphonium chloride (89.2 mg, 0.24 mmol) 
were dissolved in a mixture of MeOH (15 mL) and CH2Cl2 (15 mL). After 30 min under stirring, 
the solvent was removed and the crude mixture was purified by column chromatography on silica 
gel (eluent: CH2Cl2–MeOH, 95/5 then 90/10) to yield the complex 7 as an orange powder 
(125.0 mg, yield = 69%). 
1H RMN (400 MHz, CDCl3): δH = 3.75 (d, 1H, J = 17.1 Hz, CH2S), 4.05 (d, 1H, J = 17.1 Hz, 
CH2S), 4.41 (d, 1H, J = 18.3 Hz, CH2N), 5.39 (d, 1H, J = 18.3 Hz, CH2N), 6.97 (d, 1H, 
J = 8.3 Hz, HAr), 7.51 (m, 9H, HAr + HAr PPh4), 7.68 (m, 8H, HAr PPh4), 7.82 (m, 4H, HAr PPh4), 
8.83 (m, 1H, HAr); 
13C{1H} NMR (100.6 MHz, CDCl3): δC = 40.1 (CH2S), 61.0 (CH2N), 116.9, 
118.0, 119.9 (3CHAr), 115.2 (4CAr PPh4), 130.5, 130.7, 134.2, 134.3, 135.7, 135.8 (20CHAr PPh4), 
141.0, 171.5 (2CAr), 175.3, 186.5, 193.3 (3CO); MS (ES
−): m/z (%) 481 (60), 483 (100) [M−]; IR 
(KBr): νC O = 1644, 1635, 1610 cm
−1, νRe O = 957 cm
−1. Found: C, 51.19; H, 3.52; N, 3.24; 
C35H28N2O6PReS requires C, 51.15; H, 3.43; N, 3.41. 
4.7. 99mTc labelling
Ligand 5 (100 μL of a freshly prepared stock methanolic solution of 1 mg/mL of 5) was added to 
a buffer solution pH = 8.6 (200 μL). Successively were added SnCl2·2H2O (75 μL of a freshly 
prepared solution of 9 mg of SnCl2·2H2O in a mixture of methanol (4 mL) and HCl concentrated 
(0.5 μL)) and 99mTc-pertechnetate solution generator eluate (100 μL, 74 MBq). The vial was 
sealed with a Teflon-lined cap and the mixture was heated at 40 °C for 30 minutes. After cooling, 
the resulting complex was analysed and purified with the HPLC system described before. The 
retention time of 8 was 3.88 min. 
4.8. Biodistribution in healthy rats
All experiments were carried out in compliance with French laws relating to the conduct of 
animal experimentation. 
Before being used in the animal studies, purified complex 8 solution was filtered through a 
0.22 μm sterile filter (Millipore®) and diluted with sterile saline solutions. Male Wistar rats, about 
400 g and anaesthetised with Nesdonal®, were sacrificed 5 and 30 min post-injection (pi) (n = 3) 
after an intra-jugular injection of 300 μL of the diluted tracer solution. The organs of interest 
(liver, spleen, heart, lungs, kidneys and brain) were dissected, weighed and their radioactivity was 
measured in a Packard autogamma counter. Results, expressed as percentage of injected dose per 
organ (% ID/organ), are summarized in Table 1. The percentage radioactivity in the blood was 
calculated assuming that the whole-blood volume was 7% of the body weight. 
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